Scott Letendre, M.D. is an Associate Professor of Medicine at UCSD and former K23 Career Development Award recipient. In the past decade, Dr. Letendre has led or collaborated on many publicly and privately funded translational research projects. His influential work has focused on the risk factors and treatment of HIV-associated neurocognitive disorder (HAND) in the US and international settings. During this period, he has also mentored more than 30 trainees in patient-oriented research, including graduate and medical students, post-doctoral researchers, and junior faculty. In the proposed K24 mid-career investigator award, Dr. Letendre will expand his mentoring of junior investigators and will focus his mentoring and his own research on three main objectives. Antiretroviral treatment of the nervous system: Dr. Letendre will mentor trainees on design and performance of HAND clinical trials and CSF pharmacology projects, particularly focusing on longitudinal projects that measure all drugs in an antiretroviral regimen to better understand how drug interactions and time influence virologic and neurocognitive outcomes. Biomarker correlates of disease and treatment: Dr. Letendre will mentor trainees on measurement and analysis of biomarker data with the goal of developing a clinically useful panel for screening, diagnosis, and prognosis of HAND. This work will be supported by new equipment purchased with funds from a recent S10 Shared Instrument Grant. Coinfections in HIV-infected individuals: Dr. Letendre will work with trainees on projects that evaluate the impact on the nervous system of latent or minimally symptomatic infections with pathogens such as Plasmodium, Cytomegalovirus, Toxoplasma, and hepatitis C virus. This work will particularly focus on Dr. Letendre's existing work in international settings. Dr. Letendre will mentor trainees using a multidisciplinary approach that includes regular direct engagement, participation in R25, T32, and K30 programs at UCSD, active participation in existing research projects, support for new research projects, and networking with other investigators. Dr. Letendre will also obtain training in mentoring and analysis of longitudinal data. In summary, this K24 award will secure protected time for Dr. Letendre to mentor trainees in neuroAIDS methods, including the responsible conduct of patient- oriented research. Dr. Letendre will coordinate his efforts with other UCSD resources, including the R25- funded """"""""International Research Fellowship in NeuroAIDS"""""""", the T32-funded """"""""Training in Research on Addictions in Interdisciplinary NeuroAIDS"""""""", and the CTSA-funded """"""""Clinical and Translational Research Institute"""""""".
HIV is one of the most common causes of neurocognitive disorders in adults younger than 49 years old worldwide. This continues to be true even though antiretroviral therapy has largely transformed HIV disease to a chronic illness in many. To help address this problem, the proposed investigator award will support mentoring of scientists in the responsible conduct of patient-oriented neuroAIDS research.
|Kamat, Rujvi; McCutchan, Allen; Kumarasamy, Nagalingeswaran et al. (2017) Neurocognitive functioning among HIV-positive adults in southern India. J Neurovirol 23:750-755|
|Sakoda, Marissa E; Fazeli, Pariya L; Ellis, Ronald J et al. (2017) Higher Cystatin C Levels Are Associated With Neurocognitive Impairment in Older HIV+ Adults. J Acquir Immune Defic Syndr 74:243-249|
|Anderson, Albert M; Muñoz-Moreno, Jose A; McClernon, Daniel R et al. (2017) Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy. J Infect Dis 215:105-113|
|Yu, Chunjiang; Seaton, Melanie; Letendre, Scott et al. (2017) Plasma dickkopf-related protein 1, an antagonist of the Wnt pathway, is associated with HIV-associated neurocognitive impairment. AIDS 31:1379-1385|
|de Almeida, Sergio M; Rotta, Indianara; Ribeiro, Clea E et al. (2017) Dynamic of CSF and serum biomarkers in HIV-1 subtype C encephalitis with CNS genetic compartmentalization-case study. J Neurovirol 23:460-473|
|Ene, L; Marcotte, T D; Umlauf, A et al. (2016) Latent toxoplasmosis is associated with neurocognitive impairment in young adults with and without chronic HIV infection. J Neuroimmunol 299:1-7|
|Bharti, Ajay R; McCutchan, Allen; Deutsch, Reena et al. (2016) Latent Toxoplasma Infection and Higher Toxoplasma gondii Immunoglobulin G Levels Are Associated With Worse Neurocognitive Functioning in HIV-Infected Adults. Clin Infect Dis 63:1655-1660|
|Ma, Qing; Vaida, Florin; Wong, Jenna et al. (2016) Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients. J Neurovirol 22:170-8|
|Bharti, Ajay R; Woods, Steven Paul; Ellis, Ronald J et al. (2016) Fibroblast growth factors 1 and 2 in cerebrospinal fluid are associated with HIV disease, methamphetamine use, and neurocognitive functioning. HIV AIDS (Auckl) 8:93-9|
|Hoenigl, Martin; Pérez-Santiago, Josué; Nakazawa, Masato et al. (2016) (1?3)-?-d-Glucan: A Biomarker for Microbial Translocation in Individuals with Acute or Early HIV Infection? Front Immunol 7:404|
Showing the most recent 10 out of 57 publications